These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32098220)

  • 1. CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome.
    Suh SH; Choi HS; Kim CS; Kim IJ; Cha H; Cho JM; Ma SK; Kim SW; Bae EH
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.
    Suh SH; Choi HS; Kim CS; Kim IJ; Ma SK; Scholey JW; Kim SW; Bae EH
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome.
    Bae EH; Fang F; Williams VR; Konvalinka A; Zhou X; Patel VB; Song X; John R; Oudit GY; Pei Y; Scholey JW
    Kidney Int; 2017 Jun; 91(6):1347-1361. PubMed ID: 28249676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.
    Choi HS; Song JH; Kim IJ; Joo SY; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW; Bae EH
    Sci Rep; 2018 Aug; 8(1):11546. PubMed ID: 30068917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
    Gross O; Beirowski B; Koepke ML; Kuck J; Reiner M; Addicks K; Smyth N; Schulze-Lohoff E; Weber M
    Kidney Int; 2003 Feb; 63(2):438-46. PubMed ID: 12631109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.
    Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O
    Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.
    Widjaja AA; Shekeran SG; Adami E; Ting JGW; Tan J; Viswanathan S; Lim SY; Tan PH; Hübner N; Coffman T; Cook SA
    J Am Soc Nephrol; 2022 Apr; 33(4):718-730. PubMed ID: 35140116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.
    Bae EH; Kim IJ; Song JH; Choi HS; Kim CS; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease.
    Gross O; Girgert R; Beirowski B; Kretzler M; Kang HG; Kruegel J; Miosge N; Busse AC; Segerer S; Vogel WF; Müller GA; Weber M
    Matrix Biol; 2010 Jun; 29(5):346-56. PubMed ID: 20307660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation.
    Yu S; Gu X; Zheng Q; Liu Y; Suhas T; Du W; Xie L; Fang Z; Zhao Y; Yang M; Xu J; Wang Y; Lin MH; Pan X; Miner JH; Jin Y; Xie J
    Kidney Int; 2024 Sep; 106(3):433-449. PubMed ID: 38782199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation.
    Chen H; Yang T; Wang MC; Chen DQ; Yang Y; Zhao YY
    Phytomedicine; 2018 Mar; 42():207-218. PubMed ID: 29655688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin contributes to kidney disease progression in Alport syndrome.
    Jarad G; Knutsen RH; Mecham RP; Miner JH
    Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse.
    Hahm K; Lukashev ME; Luo Y; Yang WJ; Dolinski BM; Weinreb PH; Simon KJ; Chun Wang L; Leone DR; Lobb RR; McCrann DJ; Allaire NE; Horan GS; Fogo A; Kalluri R; Shield CF; Sheppard D; Gardner HA; Violette SM
    Am J Pathol; 2007 Jan; 170(1):110-25. PubMed ID: 17200187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDGF-D Is Dispensable for the Development and Progression of Murine Alport Syndrome.
    Firat EAM; Buhl EM; Bouteldja N; Smeets B; Eriksson U; Boor P; Klinkhammer BM
    Am J Pathol; 2024 May; 194(5):641-655. PubMed ID: 38309427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.
    Yoon GE; Jung JK; Lee YH; Jang BC; In Kim J
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Mar; 393(3):491-500. PubMed ID: 31655853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-[1-7] attenuates kidney injury in experimental Alport syndrome.
    Choi HS; Kim IJ; Kim CS; Ma SK; Scholey JW; Kim SW; Bae EH
    Sci Rep; 2020 Mar; 10(1):4225. PubMed ID: 32144368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.
    Pang M; Kothapally J; Mao H; Tolbert E; Ponnusamy M; Chin YE; Zhuang S
    Am J Physiol Renal Physiol; 2009 Oct; 297(4):F996-F1005. PubMed ID: 19640900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.
    Zhu Z; Rosenkranz KAT; Kusunoki Y; Li C; Klaus M; Gross O; Angelotti ML; Antonelli G; Cirillo L; Romagnani P; Bouteldja N; Sadr AV; Bülow RD; Boor P; Anders HJ
    J Am Soc Nephrol; 2023 Sep; 34(9):1513-1520. PubMed ID: 37428955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of C/EBPβ and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy.
    Lee E; Lee HA; Kim M; Do GY; Cho HM; Kim GJ; Jung H; Song JH; Cho JM; Kim I
    Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):226-236. PubMed ID: 30099761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis.
    Lim RR; Tan A; Liu YC; Barathi VA; Mohan RR; Mehta JS; Chaurasia SS
    Sci Rep; 2016 Feb; 6():20841. PubMed ID: 26865052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.